CN1178941C - Crf受体拮抗剂以及与其有关的方法 - Google Patents

Crf受体拮抗剂以及与其有关的方法 Download PDF

Info

Publication number
CN1178941C
CN1178941C CNB998131725A CN99813172A CN1178941C CN 1178941 C CN1178941 C CN 1178941C CN B998131725 A CNB998131725 A CN B998131725A CN 99813172 A CN99813172 A CN 99813172A CN 1178941 C CN1178941 C CN 1178941C
Authority
CN
China
Prior art keywords
alkyl
ethyl
methyl
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998131725A
Other languages
English (en)
Chinese (zh)
Other versions
CN1326458A (zh
Inventor
M
M·哈达彻
¿
郭志强
J·R·穆卡赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN1326458A publication Critical patent/CN1326458A/zh
Application granted granted Critical
Publication of CN1178941C publication Critical patent/CN1178941C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB998131725A 1998-11-12 1999-11-12 Crf受体拮抗剂以及与其有关的方法 Expired - Fee Related CN1178941C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19095898A 1998-11-12 1998-11-12
US40074499A 1999-09-21 1999-09-21
US09/190,958 1999-09-21
US09/400,744 1999-09-21

Publications (2)

Publication Number Publication Date
CN1326458A CN1326458A (zh) 2001-12-12
CN1178941C true CN1178941C (zh) 2004-12-08

Family

ID=26886600

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998131725A Expired - Fee Related CN1178941C (zh) 1998-11-12 1999-11-12 Crf受体拮抗剂以及与其有关的方法

Country Status (19)

Country Link
US (3) US6348466B1 (enExample)
EP (1) EP1129096B1 (enExample)
JP (1) JP2002529469A (enExample)
KR (1) KR20010080402A (enExample)
CN (1) CN1178941C (enExample)
AT (1) ATE240958T1 (enExample)
AU (1) AU755997B2 (enExample)
BR (1) BR9915129A (enExample)
CA (1) CA2349904A1 (enExample)
DE (1) DE69908173T2 (enExample)
DK (1) DK1129096T3 (enExample)
ES (1) ES2196898T3 (enExample)
HK (1) HK1038925B (enExample)
IL (1) IL143105A0 (enExample)
NO (1) NO20012228D0 (enExample)
NZ (1) NZ511267A (enExample)
PT (1) PT1129096E (enExample)
TR (1) TR200102178T2 (enExample)
WO (1) WO2000027850A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress
AU2001255673A1 (en) * 2000-05-01 2001-11-12 Dupont Pharmaceuticals Company Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
JP2003533526A (ja) 2000-05-18 2003-11-11 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関連する方法
US6541469B2 (en) 2000-05-18 2003-04-01 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6747034B2 (en) * 2000-11-03 2004-06-08 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP1354884B1 (en) 2000-12-28 2007-10-10 Ono Pharmaceutical Co., Ltd. Cyclopenta[d]pyrazolo[1,5-a]pyrimidine compound as crf receptor antagonist
US6583143B2 (en) 2000-12-28 2003-06-24 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
ATE320254T1 (de) * 2001-04-30 2006-04-15 Glaxo Group Ltd Crf receptor antagonisten
GB0117395D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US7273871B2 (en) 2001-07-17 2007-09-25 Sb Pharmco Puerto Rico Inc. Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
DE602004028820D1 (de) 2003-06-25 2010-10-07 Ono Pharmaceutical Co Methansulfonsäuresalz einer pyrazolopyrimidinverbindung, kristall davon und verfahren zu deren herstellung
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
JP2007515473A (ja) * 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
CN101133157A (zh) 2004-06-03 2008-02-27 阿什洛米克斯控股有限公司 诊断应激的药物和方法
US7869958B2 (en) * 2004-08-09 2011-01-11 Research Development Foundation Structure-based modulators of B1 G-protein coupled receptors
EP2433633A1 (en) 2004-08-25 2012-03-28 Ardea Biosciences, Inc. Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ES2380951T3 (es) 2005-05-05 2012-05-21 Ardea Biosciences, Inc. Diaril-purinas, -azapurinasy - desazapurinas como inhibidores no nucleósidos de la transcriptasa inversa para el tratamiento del VIH
US7595324B2 (en) 2006-11-09 2009-09-29 Ardea Biosciences, Inc. Substituted thieno[3,2-D]pyrimidines as HIV inhibitors
MX2010005776A (es) 2007-11-27 2010-08-31 Ardea Biosciences Inc Nuevos compuestos y composiciones y metodos de uso.
WO2009079412A2 (en) 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5013737A (en) * 1988-02-22 1991-05-07 American Cyanamid Company 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
CA2150483C (en) 1992-12-17 1999-09-14 Pfizer Limited Pyrazoles and pyrazolopyrimidines
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
CA2150703C (en) 1992-12-17 2002-01-08 Pfizer Limited Substituted pyrazoles
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
ES2128544T3 (es) * 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
HU219911B (hu) 1994-06-16 2001-09-28 Pfizer Inc. Pirazolo-piridin-származékok, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények
AU716993B2 (en) 1995-05-12 2000-03-16 Neurogen Corporation Novel deazapurine derivatives; a new class of CRF1 specific ligands
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
JP2000507552A (ja) 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
ES2294800T3 (es) 1996-07-24 2008-04-01 Bristol-Myers Squibb Pharma Company Azolo triazinas y pirimidinas.
AU709203B2 (en) 1996-08-06 1999-08-26 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
BR9711970A (pt) * 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
ATE213495T1 (de) 1996-09-16 2002-03-15 Du Pont Pharm Co Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands

Also Published As

Publication number Publication date
AU755997B2 (en) 2003-01-02
DE69908173D1 (de) 2003-06-26
CA2349904A1 (en) 2000-05-18
NO20012228L (no) 2001-05-04
CN1326458A (zh) 2001-12-12
EP1129096B1 (en) 2003-05-21
WO2000027850A3 (en) 2000-08-03
WO2000027850A2 (en) 2000-05-18
DE69908173T2 (de) 2004-08-19
US6723721B2 (en) 2004-04-20
NZ511267A (en) 2002-12-20
ES2196898T3 (es) 2003-12-16
US20020143008A1 (en) 2002-10-03
HK1038925A1 (en) 2002-04-04
NO20012228D0 (no) 2001-05-04
HK1038925B (en) 2003-12-05
ATE240958T1 (de) 2003-06-15
DK1129096T3 (da) 2003-09-15
KR20010080402A (ko) 2001-08-22
IL143105A0 (en) 2002-04-21
EP1129096A2 (en) 2001-09-05
US20040229879A1 (en) 2004-11-18
AU1819900A (en) 2000-05-29
US6348466B1 (en) 2002-02-19
BR9915129A (pt) 2001-08-07
PT1129096E (pt) 2003-09-30
TR200102178T2 (tr) 2002-01-21
JP2002529469A (ja) 2002-09-10

Similar Documents

Publication Publication Date Title
CN1178941C (zh) Crf受体拮抗剂以及与其有关的方法
AU2001283955B2 (en) Piperazine derivatives
ES2247478T3 (es) Azolo-pirimidinas.
JP6928629B2 (ja) Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ
EP3112370A1 (en) Tricyclic heterocyclic compounds and jak inhibitors
EP1637521A1 (en) Novel tricyclic heterocycle compound
CN1328559A (zh) Crf受体拮抗剂以及与其有关的方法
KR20080046232A (ko) 피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도
CN101918408A (zh) 作为磷酸二酯酶10的抑制剂的芳基和杂芳基稠合的咪唑并[1,5-a]吡嗪
CN1692116A (zh) 腺苷A2a受体拮抗剂
CN1203234A (zh) 三环类吡唑衍生物
CN1239482C (zh) 烟碱性受体激动剂的正调节剂
CN1246860A (zh) 3－芳基取代的吡唑并[4,3－d]嘧啶衍生物;促肾上腺皮质激素释放因子受体(CRF1 )特异性配体
CN103717593A (zh) 调节激酶的组合物和方法
JP2020507606A (ja) カルシウムチャネル阻害剤
CN1784230A (zh) 烟碱性乙酰胆碱受体的正向调节剂
WO2002072101A1 (en) A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
JP2024520396A (ja) 置換されるカルバメート大環状化合物および関連のある治療方法
WO2006068164A1 (ja) 三環式化合物およびその用途
JP2003533530A (ja) Ｃｒｆレセプターアンタゴニスト
ES2207614T3 (es) Antagonistas del receptor de crf y metodos relacionados con estos.
US10562852B2 (en) Crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile
CN1809574A (zh) 喹啉3－氨基苯并二氢吡喃衍生物
MXPA01004800A (en) Crf receptor antagonists and methods relating thereto
ZA200104442B (en) CRF receptor antagonists and methods relating thereto.

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee